Skip to main content
SpringerLink
Log in

Predicting the Response to Chemotherapy in Gastric Adenocarcinoma: Who Benefits from Neoadjuvant Chemotherapy?

  • Conference paper
  • First Online:
Early Gastrointestinal Cancers

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 196))

Abstract

Despite a decline in the overall incidence, gastric adenocarcinoma remains the second most common cause of cancer death worldwide and thus a significant global health problem. Even in early-stage locoregional confined disease the 5-year survival rarely exceeds 25–35 %. Randomized trials have demonstrated a benefit from neoadjuvant and perioperative chemotherapy. However the optimal approach in individual patients is not clear and remains controversial. A consistent finding is that patients who have a histopathological response to neoadjuvant therapy are more likely to receive a survival benefit. These clinical data provide a strong argument for the urgent development of methods to predict histopathological response to neoadjuvant therapies for gastric adenocarcinomas. Published data demonstrate that clinico-pathological features (tumour histology and location), imaging through metabolic response by FDG-PET and tissue/molecular biomarkers may all have a predictive value for neoadjuvant therapies. However it is still uncertain from published data whether or not they will be useful for clinical decision making in individual patients. Existing candidate biomarkers need to be properly qualified and validated and novel biomarkers are required and an optimal approach should involve the combination and integration of clinical, imaging, pathological and molecular biomarkers.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Notes

  1. 1.

    http://clinicaltrials.gov Combination chemotherapy with or without bevacizumab in treating patients with previously untreated stomach cancer, gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery (ST03).

  2. 2.

    http://clinicaltrials.gov A randomised open-labelled multicentre trial of the efficacy of epirubicin, oxaliplatin and capecitabine (EOX) with or without panitumumab in previously untreated advanced oesophago-gastric cancer.

  3. 3.

    http://clinicaltrials.gov Erbitux in combination with xeloda and cisplatin in advanced esophago-gastric cancer (EXPAND).

  4. 4.

    http://clinicaltrials.gov Trial evaluating the efficacy and tolerance of perioperative chemotherapywith 5FU-cisplatin-cetuximab in adenocarcinomas of the stomach and gastroesophageal junction. Phase II single arm, multicenter.

References

  • Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

    Google Scholar 

  • Bang YJ, Kang YK, Kang WK, Boku N, Chung HC, Chen JS, Doi T, Sun Y, Shen L, Qin S, Ng WT, Tursi JM, Lechuga MJ, Lu DR, Ruiz-Garcia A, Sobrero A (2011) Phase II study of sunitinib as second-line treatment for advanced gastric cancer. Invest New Drugs 29:1449–1458

    Google Scholar 

  • Bataille F, Rummele P, Dietmaier W, Gaag D, Klebl F, Reichle A, Wild P, Hofstadter F, Hartmann A (2003) Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer. Mol Pathol 56:286–292

    Google Scholar 

  • Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Bottcher K, Siewert JR, Hofler H (2003) Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 98:1521–1530

    Google Scholar 

  • Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T (2006) Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12:3297–3305

    Google Scholar 

  • Bentrem D, Gerdes H, Tang L, Brennan M, Coit D (2007) Clinical correlation of endoscopic ultrasonography with pathologic stage and outcome in patients undergoing curative resection for gastric cancer. Ann Surg Oncol 14:1853–1859

    Google Scholar 

  • Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M (2005) Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 23:4330–4337

    Google Scholar 

  • Boku N, Chin K, Hosokawa K, Ohtsu A, Tajiri H, Yoshida S, Yamao T, Kondo H, Shirao K, Shimada Y, Saito D, Hasebe T, Mukai K, Seki S, Saito H, Johnston PG (1998) Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum. Clin Cancer Res 4:1469–1474

    Google Scholar 

  • Brucher BL, Becker K, Lordick F, Fink U, Sarbia M, Stein H, Busch R, Zimmermann F, Molls M, Hofler H, Siewert JR (2006) The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer 106:2119–2127

    Google Scholar 

  • Brucher BL, Swisher SG, Konigsrainer A, Zieker D, Hartmann J, Stein H, Kitagawa Y, Law S, Ajani JA (2009) Response to preoperative therapy in upper gastrointestinal cancers. Ann Surg Oncol 16:878–86

    Google Scholar 

  • Burke EC, Karpeh MS, Conlon KC, Brennan MF (1997) Laparoscopy in the management of gastric adenocarcinoma. Ann Surg 225:262–267

    Google Scholar 

  • Cunningham SC, Kamangar F, Kim MP, Hammoud S, Haque R, Maitra A, Montgomery E, Heitmiller RE, Choti MA, Lillemoe KD, Cameron JL, Yeo CJ, Schulick RD (2005) Survival after gastric adenocarcinoma resection: eighteen-year experience at a single institution. J Gastrointest Surg 9:718–725

    Google Scholar 

  • Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, Participants MT (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

    Google Scholar 

  • Dassen AE, Lips DJ, Hoekstra CJ, Pruijt JF, Bosscha K (2009) FDG-PET has no definite role in preoperative imaging in gastric cancer. Eur J Surg Oncol 35:449–455

    Google Scholar 

  • Diasio RB, Harris BE (1989) Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215–237

    Google Scholar 

  • Fareed KR, Kaye P, Soomro IN, Ilyas M, Martin S, Parsons SL, Madhusudan S (2009) Biomarkers of response to therapy in oesophago-gastric cancer. Gut 58:127–143

    Google Scholar 

  • Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehme A, Christen RD, Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56:4881–4886

    Google Scholar 

  • Fukuda H, Takiguchi N, Koda K, Oda K, Seike K, Miyazaki M (2006) Thymidylate synthase and dihydropyrimidine dehydrogenase are related to histological effects of 5-fluorouracil and cisplatin neoadjuvant chemotherapy for primary gastric cancer patients. Cancer Invest 24:235–241

    Google Scholar 

  • Ghaderi A, Vasei M, Maleck-Hosseini SA, Gharesi-Fard B, Khodami M, Doroudchi M, Modjtahedi H (2002) The expression of c-erbB-1 and c-erbB-2 in Iranian patients with gastric carcinoma. Pathol Oncol Res 8:252–256

    Google Scholar 

  • Goekkurt E, Hoehn S, Wolschke C, Wittmer C, Stueber C, Hossfeld DK, Stoehlmacher J (2006) Polymorphisms of glutathione S-transferases (GST) and thymidylate synthase (TS)–novel predictors for response and survival in gastric cancer patients. Br J Cancer 94:281–286

    Google Scholar 

  • Grundei T, Vogelsang H, Ott K, Mueller J, Scholz M, Becker K, Fink U, Siewert JR, Hofler H, Keller G (2000) Loss of heterozygosity and microsatellite instability as predictive markers for neoadjuvant treatment in gastric carcinoma. Clin Cancer Res 6:4782–4788

    Google Scholar 

  • Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J (2004) Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med 128:765–770

    Google Scholar 

  • Hudis CA (2007) Trastuzumab–mechanism of action and use in clinical practice. N Engl J Med 357:39–51

    Google Scholar 

  • Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Google Scholar 

  • Iqbal S, Goldman B, Fenoglio-Preiser CM, Lenz HJ, Zhang W, Danenberg KD, Shibata SI, Blanke CD (2011) Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 22:2610–2615

    Google Scholar 

  • Ishikawa Y, Kubota T, Otani Y, Watanabe M, Teramoto T, Kumai K, Takechi T, Okabe H, Fukushima M, Kitajima M (2000) Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 91:105–112

    Google Scholar 

  • Jonckheere N, Van Seuningen I (2008) The membrane-bound mucins: how large O-glycoproteins play key roles in epithelial cancers and hold promise as biological tools for gene-based and immunotherapies. Crit Rev Oncog 14:177–196

    Google Scholar 

  • Jonckheere N, Van Seuningen I (2010) The membrane-bound mucins: From cell signalling to transcriptional regulation and expression in epithelial cancers. Biochimie 92:1–11

    Google Scholar 

  • Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150

    Google Scholar 

  • Kameyama R, Yamamoto Y, Izuishi K, Takebayashi R, Hagiike M, Murota M, Kaji M, Haba R, Nishiyama Y (2009) Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 36:382–388

    Google Scholar 

  • Kaur A, Dasanu CA (2011) Targeting the HER2 pathway for the therapy of lower esophageal and gastric adenocarcinoma. Expert Opin Pharmacother 12:2493–2503

    Google Scholar 

  • Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, Fujii H (2007) Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer 97:494–501

    Google Scholar 

  • Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ (2008) Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 8:148

    Google Scholar 

  • Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG (2007) Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25:3719–3725

    Google Scholar 

  • Kikuyama S, Inada T, Shimizu K, Miyakita M, Ogata Y (2001) p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 21:2149–2153

    Google Scholar 

  • Koga H, Sasaki M, Kuwabara Y, Hiraka K, Nakagawa M, Abe K, Kaneko K, Hayashi K, Honda H (2003) An analysis of the physiological FDG uptake pattern in the stomach. Ann Nucl Med 17:733–738

    Google Scholar 

  • Koizumi W, Saigenji K, Nakamaru N, Okayasu I, Kurihara M (1999) Prediction of response to 5′-deoxy-5-fluorouridine (5′-DFUR) in patients with inoperable advanced gastric cancer by immunostaining of thymidine phosphorylase/platelet-derived endothelial cell growth factor. Oncology 56:215–222

    Google Scholar 

  • Kono A, Hara Y, Sugata S, Karube Y, Matsushima Y, Ishitsuka H (1983) Activation of 5′-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem Pharm Bull (Tokyo) 31:175–178

    Google Scholar 

  • Kwon HC, Roh MS, Oh SY, Kim SH, Kim MC, Kim JS, Kim HJ (2007) Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann Oncol 18:504–509

    Google Scholar 

  • Lenz HJ, Leichman CG, Danenberg KD, Danenberg PV, Groshen S, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Garcia Y, Li J, Leichman L (1996) Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 14:176–182

    Google Scholar 

  • Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Hofler H, Fink U, Peschel C, Schwaiger M, Siewert JR (2007) PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncol 8:797–805

    Google Scholar 

  • Lordick F, Luber B, Lorenzen S, Hegewisch-Becker S, Folprecht G, Woll E, Decker T, Endlicher E, Rothling N, Schuster T, Keller G, Fend F, Peschel C (2010) Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Br J Cancer 102:500–505

    Google Scholar 

  • Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA (1999) Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 229:303–308

    Google Scholar 

  • Lu JW, Gao CM, Wu JZ, Cao HX, Tajima K, Feng JF (2006) Polymorphism in the 3′-untranslated region of the thymidylate synthase gene and sensitivity of stomach cancer to fluoropyrimidine-based chemotherapy. J Hum Genet 51:155–160

    Google Scholar 

  • Macdonald JS (2009) Adopting postoperative chemoradiotherapy in resected gastric cancer. Gastrointest Cancer Res 3:245–246

    Google Scholar 

  • Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730

    Google Scholar 

  • Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G, et al. (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer 73:2680–2686

    Google Scholar 

  • Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C (2011) The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study. Ann Surg 254:684–693 (discussion 693)

    Google Scholar 

  • Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Silberman H, Baranda J, Konda B, Leichman L (1998) ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 16:309–316

    Google Scholar 

  • Milano G, Etienne MC, Pierrefite V, Barberi-Heyob M, Deporte-Fety R, Renee N (1999) Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br J Cancer 79: 627–630

    Google Scholar 

  • Moehler M, Mueller A, Hartmann JT, Ebert MP, Al-Batran SE, Reimer P, Weihrauch M, Lordick F, Trarbach T, Biesterfeld S, Kabisch M, Wachtlin D, Galle PR (2011) An open-label, multicentre biomarker-oriented AIO phase II trial of sunitinib for patients with chemo-refractory advanced gastric cancer. Eur J Cancer 47:1511–1520

    Google Scholar 

  • Nagashima F, Boku N, Ohtsu A, Yoshida S, Hasebe T, Ochiai A, Sakata Y, Saito H, Miyata Y, Hyodo I, Ando M (2005) Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin. Jpn J Clin Oncol 35:714–719

    Google Scholar 

  • Nakata B, Chung KH, Ogawa M, Ogawa Y, Yanagawa K, Muguruma K, Inoue T, Yamashita Y, Onoda N, Maeda K, Sawada T, Sowa M (1998) p53 protein overexpression as a predictor of the response to chemotherapy in gastric cancer. Surg Today 28:595–598

    Google Scholar 

  • Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, Muller M, Lordick F, Fink U, Rudiger Siewert J, Hofler H, Keller G (2005) Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin Cancer Res 11:3025–3031

    Google Scholar 

  • Nishina T, Hyodo I, Miyaike J, Inaba T, Suzuki S, Shiratori Y (2004) The ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase in tumour tissues of patients with metastatic gastric cancer is predictive of the clinical response to 5′-deoxy-5-fluorouridine. Eur J Cancer 40:1566–1571

    Google Scholar 

  • Novotny AR, Schuhmacher C, Busch R, Kattan MW, Brennan MF, Siewert JR (2006) Predicting individual survival after gastric cancer resection: validation of a U.S.-derived nomogram at a single high-volume center in Europe. Ann Surg 243:74–81

    Google Scholar 

  • Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang YK (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol 29:3968–3976

    Google Scholar 

  • Okada E, Murai Y, Matsui K, Isizawa S, Cheng C, Masuda M, Takano Y (2001) Survivin expression in tumor cell nuclei is predictive of a favorable prognosis in gastric cancer patients. Cancer Lett 163:109–116

    Google Scholar 

  • Ott K, Fink U, Becker K, Stahl A, Dittler HJ, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert JR, Weber WA (2003) Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 21:4604–4610

    Google Scholar 

  • Ott K, Vogelsang H, Mueller J, Becker K, Muller M, Fink U, Siewert JR, Hofler H, Keller G (2003) Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 9:2307–2315

    Google Scholar 

  • Ott K, Vogelsang H, Marton N, Becker K, Lordick F, Kobl M, Schuhmacher C, Novotny A, Mueller J, Fink U, Ulm K, Siewert JR, Hofler H, Keller G (2006) The thymidylate synthase tandem repeat promoter polymorphism: A predictor for tumor-related survival in neoadjuvant treated locally advanced gastric cancer. Int J Cancer 119:2885–2894

    Google Scholar 

  • Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR (2006) Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 24:4692–4698

    Google Scholar 

  • Ott K, Herrmann K, Lordick F, Wieder H, Weber WA, Becker K, Buck AK, Dobritz M, Fink U, Ulm K, Schuster T, Schwaiger M, Siewert JR, Krause BJ (2008) Early metabolic response evaluation by fluorine-18 fluorodeoxyglucose positron emission tomography allows in vivo testing of chemosensitivity in gastric cancer: long-term results of a prospective study. Clin Cancer Res 14:2012–2018

    Google Scholar 

  • Ott K, Lordick F, Becker K, Ulm K, Siewert J, Hofler H, Keller G (2008) Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis 23:773–782

    Google Scholar 

  • Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR (2008) The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer 11:1–9

    Google Scholar 

  • Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, zum Buschenfelde CM, Buck AK, Wilhelm D, Ebert MP, Peschel C, Schwaiger M, Lordick F, Krause BJ (2011) Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol 18:3316–3323

    Google Scholar 

  • Piessen G, Messager M, Leteurtre E, Jean-Pierre T, Mariette C (2009) Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 250:878–887

    Google Scholar 

  • Piessen G, Amielh D, Messager M, Vinatier E, Leteurtre E, Triboulet JP, Mariette C (2012) Is pretreatment endoscopic biopsy a good predictor of signet ring cell histology in gastric carcinoma? World J Surg 36:346–354

    Google Scholar 

  • Pinto C, Di Fabio F, Siena S, Cascinu S, Rojas Llimpe FL, Ceccarelli C, Mutri V, Giannetta L, Giaquinta S, Funaioli C, Berardi R, Longobardi C, Piana E, Martoni AA (2007) Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). Ann Oncol 18:510–517

    Google Scholar 

  • Pinto C, Di Fabio F, Barone C, Siena S, Falcone A, Cascinu S, Rojas Llimpe FL, Stella G, Schinzari G, Artale S, Mutri V, Giaquinta S, Giannetta L, Bardelli A, Martoni AA (2009) Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study). Br J Cancer 101:1261–1268

    Google Scholar 

  • Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820

    Google Scholar 

  • Sarela AI, Miner TJ, Karpeh MS, Coit DG, Jaques DP, Brennan MF (2006) Clinical outcomes with laparoscopic stage M1, unresected gastric adenocarcinoma. Ann Surg 243:189–195

    Google Scholar 

  • Shah MA, Coit YH et al. (2007) A phase II study of preoperative chemotherapy with irinotecan (CPT) and cisplatin (CIS) for gastric cancer (NCI 5917): FDG-PET/CT predicts patient out-come. J Clin Oncol 102(2):135–140

    Google Scholar 

  • Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D, O’Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201–5206

    Google Scholar 

  • Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP (2011) Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol 29:868–874

    Google Scholar 

  • Shoda H, Kakugawa Y, Saito D, Kozu T, Terauchi T, Daisaki H, Hamashima C, Muramatsu Y, Moriyama N, Saito H (2007) Evaluation of 18F-2-deoxy-2-fluoro-glucose positron emission tomography for gastric cancer screening in asymptomatic individuals undergoing endoscopy. Br J Cancer 97:1493–1498

    Google Scholar 

  • Smith BR, Stabile BE (2009) Extreme aggressiveness and lethality of gastric adenocarcinoma in the very young. Arch Surg 144:506–510

    Google Scholar 

  • Sun W, Powell M, O’Dwyer PJ, Catalano P, Ansari RH, Benson AB (2010) 3rd Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203. J Clin Oncol 28:2947–2951

    Google Scholar 

  • Terashima M, Fujiwara H, Takagane A, Abe K, Araya M, Irinoda T, Yonezawa H, Nakaya T, Oyama K, Takahashi M, Saito K (2002) Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 38:2375–2381

    Google Scholar 

  • Terashima M, Fujiwara H, Takagane A, Abe K, Irinoda T, Nakaya T, Yonezawa H, Oyama K, Saito K, Kanzaki N, Ohtani S, Nemoto T, Hoshino Y, Kogure M, Gotoh M (2003) Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer 6(Suppl 1):71–81

    Google Scholar 

  • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216

    Google Scholar 

  • Vallbohmer D, Drebber U, Schneider PM, Baldus S, Bollschweiler E, Brabender J, Warnecke-Eberz U, Monig S, Holscher AH, Metzger R (2009) Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis. J Surg Oncol 99:409–413

    Google Scholar 

  • Vallbohmer D, Holscher AH, Schneider PM, Schmidt M, Dietlein M, Bollschweiler E, Baldus S, Alakus H, Brabender J, Metzger R, Monig SP (2010) [18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol 102:135–140

    Google Scholar 

  • Wang TT, Qian XP, Liu BR (2007) Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J Gastroenterol 13:2784–2790

    Google Scholar 

  • Warnecke-Eberz U, Hokita S, Xi H, Higashi H, Baldus SE, Metzger R, Brabender J, Bollschweiler E, Mueller RP, Dienes HP, Hoelscher AH, Schneider PM (2005) Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer. Oncol Rep 13:1241–1246

    Google Scholar 

  • Watanabe H JJ, Sobin LH (1990) Histological typing of oesophageal and gastric tumors. WHO international classification of tumurs. Springer, Berlin

    Google Scholar 

  • Weber G, Nagai M, Natsumeda Y, Ichikawa S, Nakamura H, Eble JN, Jayaram HN, Zhen WN, Paulik E, Hoffman R et al. (1991) Regulation of de novo and salvage pathways in chemotherapy. Adv Enzyme Regul 31:45–67

    Google Scholar 

  • Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschlager G, Busch R, Siewert JR, Schwaiger M, Fink U (2001) Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19:3058–3065

    Google Scholar 

  • Wells P, Aboagye E, Gunn RN, Osman S, Boddy AV, Taylor GA, Rafi I, Hughes AN, Calvert AH, Price PM, Newell DR (2003) 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 95:675–682

    Google Scholar 

  • Wieder HA, Geinitz H, Rosenberg R, Lordick F, Becker K, Stahl A, Rummeny E, Siewert JR, Schwaiger M, Stollfuss J (2007) PET imaging with [18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 34:878–883

    Google Scholar 

  • Witton CJ, Reeves JR, Going JJ, Cooke TG, Bartlett JM (2003) Expression of the HER1–4 family of receptor tyrosine kinases in breast cancer. J Pathol 200:290–297

    Google Scholar 

  • Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721

    Google Scholar 

  • Yeh KH, Shun CT, Chen CL, Lin JT, Lee WJ, Lee PH, Chen YC, Cheng AL (1998) High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 82:1626–1631

    Google Scholar 

  • Yun M, Choi HS, Yoo E, Bong JK, Ryu YH, Lee JD (2005) The role of gastric distention in differentiating recurrent tumor from physiologic uptake in the remnant stomach on 18F-FDG PET. J Nucl Med 46:953–957

    Google Scholar 

  • Yun M, Lim JS, Noh SH, Hyung WJ, Cheong JH, Bong JK, Cho A, Lee JD (2005) Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT. J Nucl Med 46:1582–1588

    Google Scholar 

Download references

Conflicts of Interest

The authors declare that they have no competing interests.

Funding Source:

none

Author information

Authors and Affiliations

  1. Department of Digestive and Oncological Surgery, University Hospital Claude Huriez Regional University Hospital Center, Place de Verdun, 59037, Lille Cedex, France

    William B. Robb & Christophe Mariette

  2. University of Lille 2, Lille, France

    Christophe Mariette

  3. Inserm, UMR837, Team 5 “Mucins epithelial differentiation and carcinogenesis”, JPARC, Rue Michel Polonovski, 59045, Lille cedex, France

    Christophe Mariette

Authors
  1. William B. Robb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe Mariette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christophe Mariette .

Editor information

Editors and Affiliations

  1. Tumor- und Brustzentrum ZeTuP AG, Rorschacherstr. 150, St. Gallen, 9006, Switzerland

    Florian Otto

  2. Rheinstr. 2, Saarbrücken, 66113, Germany

    Manfred P. Lutz

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Robb, W.B., Mariette, C. (2012). Predicting the Response to Chemotherapy in Gastric Adenocarcinoma: Who Benefits from Neoadjuvant Chemotherapy?. In: Otto, F., Lutz, M. (eds) Early Gastrointestinal Cancers. Recent Results in Cancer Research, vol 196. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-31629-6_17

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-31629-6_17

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-31628-9

  • Online ISBN: 978-3-642-31629-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation